News
ESAIY
7.55
NaN%
--
Weekly Report: what happened at ESAIY last week (0907-0911)?
Weekly Report · 8h ago
Weekly Report: what happened at ESAIY last week (0831-0904)?
Weekly Report · 09/07 09:32
Weekly Report: what happened at ESAIY last week (0824-0828)?
Weekly Report · 08/31 09:35
GSK: Still One Of My Top Healthcare Picks
Seeking Alpha · 08/27 12:08
Weekly Report: what happened at ESAIY last week (0817-0821)?
Weekly Report · 08/24 09:35
Weekly Report: what happened at ESAIY last week (0810-0814)?
Weekly Report · 08/17 09:36
Lantheus gains FDA nod for tau PET imaging agent in Alzheimer’s
Seeking Alpha · 08/14 12:31
Weekly Report: what happened at ESAIY last week (0803-0807)?
Weekly Report · 08/10 09:34
Weekly Report: what happened at ESAIY last week (0727-0731)?
Weekly Report · 08/03 09:33
Eisai GAAP EPS of ¥64.71, revenue of ¥234.3B; updates FY 2026 outlook
Seeking Alpha · 08/03 07:23
Biogen raises revenue outlook as growth portfolio drives Q2 beat
Seeking Alpha · 07/29 11:05
ProMIS jumps after early-stage trial data for Alzheimer’s therapy
Seeking Alpha · 07/28 17:55
Weekly Report: what happened at ESAIY last week (0720-0724)?
Weekly Report · 07/27 09:35
Weekly Report: what happened at ESAIY last week (0713-0717)?
Weekly Report · 07/20 09:34
Biogen nabs approval of subcutaneous version of Leqembi for initiation dose
Seeking Alpha · 07/13 22:56
Weekly Report: what happened at ESAIY last week (0706-0710)?
Weekly Report · 07/13 09:34
Weekly Report: what happened at ESAIY last week (0629-0703)?
Weekly Report · 07/06 09:36
Weekly Report: what happened at ESAIY last week (0622-0626)?
Weekly Report · 06/29 09:34
Weekly Report: what happened at ESAIY last week (0615-0619)?
Weekly Report · 06/22 09:38
Weekly Report: what happened at ESAIY last week (0608-0612)?
Weekly Report · 06/15 09:39
More
Webull provides a variety of real-time ESAIY stock news. You can receive the latest news about Eisai Co Ltd through multiple platforms. This information may help you make smarter investment decisions.
About ESAIY
Eisai Co Ltd is a Japan-based pharmaceutical company mainly engaged in the research and development, manufacture, sale, import and export of pharmaceuticals. The Company operates in two business segments. The Pharmaceutical segment is engaged in the research, development, manufacture and sale of pharmaceuticals for medical use, generic drugs, general medicines, among others. The segment operates in five regions including Japan, Americas (North America), China, EMEA (Europe, Middle East, Africa, Russia, Oceania), Asia and Latin America (Korea, Taiwan, India, ASEAN, Latin America). The Others segment is involved in license revenues and pharmaceutical raw materials business. The Company is also engaged in the provision of brands such as the anticancer drugs Lembima and Halaven on the nerve and oncology areas.